Company Overview

al use only For pers Psi-GAD Generalized Anxiety Disorder Problem GAD is diffuse, excessive, uncontrollable anxiety that is not restricted to any specific environmental circumstances. Treatment of GAD remains inadequate, with less than half of patients achieving remissions with currently accepted treatments. Solution Psilocybin works by facilitating access to fundamental causes of anxiety and providing a remarkable opportunity for patients to make real and lasting changes via psychotherapy. Clinical development status Asset Psilocybin ("Psi-GAD") Generalized Anxiety Disorder* Preclinical FDA Incannex Pre-IND + PSI-GAD Australian clinical trial investigating safety and efficacy in GAD patients. Phase 2a CT FDA IND FDA Phase 2 Addressable Market US & AUS COMBINED 8M people Lead Assets ●●●●●●●●● An estimated 7M people in the US and 1M in Australia have moderate to severe GAD at any point in time FDA Phase 3 (2) https://www.prnewswire.com/news-releases/global-generalized-anxiety-disorder-market-is-estimated-to-grow-at- Anticipated Milestones 25-cagr-to-reach-75-billion-by-2023-679279763.html Phase 2a mid trial results "readout" Q4 2022 Open FDA IND Investor Presentation 31

View entire presentation